|
1
|
Fisher RI, Gaynor ER, Dahlberg S, et al:
Comparison of a standard regimen (CHOP) with three intensive
chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J
Med. 328:1002–1006. 1993.PubMed/NCBI
|
|
2
|
Coiffier B, Lepage E, Briere J, et al:
CHOP chemotherapy plus rituximab compared with CHOP alone in
elderly patients with diffuse large B-cell lymphoma. N Engl J Med.
346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Philip T, Guglielmi C, Hagenbeek A, et al:
Autologous bone marrow transplantation as compared with salvage
chemotherapy in relapses of chemosensitive non-Hodgkin’s lymphoma.
N Engl J Med. 333:1540–1545. 1995.PubMed/NCBI
|
|
4
|
Ardeshna KM, Kakouros N, Qian W, et al:
Conventional second-line salvage chemotherapy regimens are not
warranted in patients with malignant lymphomas who have progressive
disease after first-line salvage therapy regimens. Br J Haematol.
130:363–372. 2005. View Article : Google Scholar
|
|
5
|
Casasnovas RO, Haioun C, Dumontet C, et
al: Phase II study of 3-hour infusion of high dose paclitaxel in
refractory and relapsed aggressive non-Hodgkin’s lymphomas. Groupe
d’Etude des Lymphomes de l’Adulte. Haematologica. 85:502–507.
2000.PubMed/NCBI
|
|
6
|
Gobbi PG, Valentino F, Lambelet P, et al:
Shortened and intensified MJMA: an effective salvage therapy for
relapsed and refractory lymphomas and a strong mobilizer of PBSCs.
Bone Marrow Transplant. 44:19–25. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sica S, Di Mario A, Salutari P, et al:
Sequential peripheral blood progenitor cell transplantation after
mobilization with salvage chemotherapy and G-CSF in patients with
resistant lymphoma. Am J Hematol. 46:18–23. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
La Barbera EO, Chiusolo P, Laurenti L, et
al: MiCMA: an alternative treatment for refractory or recurrent
Hodgkin’s disease. Ann Oncol. 11:867–871. 2000.
|
|
9
|
Oyan B, Koc Y, Ozdemir E, et al:
Ifosfamide, idarubicin and etoposide in relapsed/refractory Hodgkin
disease and non-Hodgkin lymphomas: a salvage regimen with high
response rates before autologous stem cell transplantation. Biol
Blood Marrow Transplant. 11:688–697. 2005. View Article : Google Scholar
|
|
10
|
Zhou SY, Shi YK, He XH, et al: Treatment
effect of DICE regimen on patients with relapsed or refractory
intermediate and high-grade non-Hodgkin’s lymphoma. Ai Zheng.
24:465–469. 2005.
|
|
11
|
Clavio M, Garrone A, Pierri I, et al:
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral
blood progenitor cell transplant: A feasible and effective salvage
treatment for lymphoid malignancies. Oncol Rep. 14:933–940.
2005.
|
|
12
|
Menzel H, Müller A, von Schilling C, Licht
T, Peschel C and Keller U: Ifosfamide, epirubicin and etoposide
rituximab in refractory or relapsed B-cell lymphoma: analysis of
remission induction and stem cell mobilization. Leuk Lymphoma.
49:1337–1344. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bishton MJ, Lush RJ, Byrne JL, Russell NH,
Shaw BE and Haynes AP: Ifosphamide, etoposide and epirubicin is an
effective combined salvage and peripheral blood stem cell
mobilisation regimen for transplant-eligible patients with
non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol.
36:752–761. 2007. View Article : Google Scholar
|
|
14
|
Hertzberg MS, Crombie C, Benson W, Taper
J, Gottlieb D and Bradstock KF: Outpatient fractionated ifosfamide,
carboplatin, and etoposide as salvage therapy in relapsed and
refractory non-Hodgkin’s lymphoma. Ann Oncol. 17(Suppl 4): 25–30.
2006.
|
|
15
|
Aurer I, Metrovic Z, Nemet D, et al:
Treatment of relapsed or refractory aggressive non-Hodgkin lymphoma
with two ifosfamide-based regimens, IMVP and ICE. J Chemother.
20:640–644. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Simpson L, Ansell SM, Colgan JP, et al:
Effectiveness of second line salvage chemotherapy with ifosfamide,
carboplatin and etoposide in patients with relapsed diffuse large
B-cell lymphoma not responding to cisplatinum, cytosine arabinoside
and dexamethasone. Leuk Lymphoma. 48:1332–1337. 2007. View Article : Google Scholar
|
|
17
|
Kewalramani T, Zelenetz AD, Nimer SD, et
al: Rituximab and ICE as second-line therapy before autologous stem
cell transplantation for relapsed or primary refractory diffuse
large B-cell lymphoma. Blood. 103:3684–3688. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shütt P, Passon J, Ebeling P, et al:
Ifosfamide, etoposide, cytarabine and dexamethasone as salvage
treatment followed by high-dose cyclophosphamide, melphalan and
etoposide with autologous peripheral blood stem cell
transplantation for relapsed or refractory lymphomas. Eur J
Haematol. 78:93–101. 2007.
|
|
19
|
Müller-Beissenhirtz H, Kasper C, Nückel H
and Dührsen U: Gemcitabine, vinorelbine and prednisone for
refractory or relapsed aggressive lymphoma, result of a phase II
single center study. Ann Hematol. 84:796–801. 2005.PubMed/NCBI
|
|
20
|
Papageorgiou ES, Tsirigotis P, Dimopoulos
M, et al: Combination chemotherapy with gemcitabine and vinorelbine
in the treatment of relapsed or refractory diffuse large B-cell
lymphoma: a phase-II trial by the Hellenic Cooperative Oncology
Group. Eur J Haematol. 75:124–129. 2005. View Article : Google Scholar
|
|
21
|
Avilès A, Neri N, Huerta-Guzman J and
Fernandez R: Gemcitabine and cisplatin in refractory malignant
lymphoma. Oncology. 66:197–200. 2004.PubMed/NCBI
|
|
22
|
Crump M, Baetz T, Couban S, et al:
Gemcitabine, dexamethasone and cisplatin in patients with recurrent
or refractory aggressive histology B-cell non-Hodgkin lymphoma.
Cancer. 101:1835–1842. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fan Y, Huang ZY, Luo LH and Yu HF:
Efficacy of GDP regimen (gemcitabine, dexamethasone and cisplatin)
on relapsed or refractory aggressive non-Hodgkin’s lymphoma: a
report of 24 cases. Ai Zheng. 27:1222–1225. 2008.
|
|
24
|
Di Renzo N, Brugnatelli M, Montanini A, et
al: Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP)
as salvage therapy in relapsed or refractorry aggressive
non-Hodgkin’s lymphoma: results of a phase II study conducted by
the Gruppo Italiano per lo Studio dei Linfomi. Leuk Lymphoma.
47:473–479. 2006.
|
|
25
|
Corazzelli G, Russo F, Capobianco G,
Marcacci G, Della Cioppa P and Pinto A: Gemcitabine, ifosfamide,
oxaliplatin and rituximab (R-GIFOX), a new effective
cytoreductive/mobilizing salvage regimen for relapsed and
refractory aggressive non-Hodgkin’s lymphoma: results of a pilot
study. Ann Oncol. 17(Suppl 4): 18–24. 2006.PubMed/NCBI
|
|
26
|
Lòpez A, Gutierrez A, Palacios A, et al:
GEMOX-R regimen is a highly effective salvage regimen in patients
with refractory/relapsing diffuse large-cell lymphoma: a phase II
study. Eur J Haematol. 80:127–132. 2007.PubMed/NCBI
|
|
27
|
Ng M, Waters J, Cunnigham D, et al:
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an
effective salvage regimen in patients with relapsed and refractory
lymphoma. Br J Cancer. 92:1352–1357. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sirohi B, Cunningham D, Norman A, et al:
Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or
without rituximab in relapsed and refractory patients with diffuse
large B-cell lymphoma. Hematology. 12:149–153. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oki Y, Pro B, Fayad LE, et al: Phase 2
study of gemcitabine in combination with rituximab in patients with
recurrent or refractory Hodgkin lymphoma. Cancer. 112:831–836.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Olivieri A, Brunori M, Capelli D, et al:
Salvage therapy with an outpatient DHAP schedule followed by PBSC
transplantation in 79 lymphoma patients: an intention to mobilize
and transplant analysis. Eur J Haematol. 72:10–17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mey UJ, Orlopp KS, Flieger D, et al:
Dexamethasone, high-dose cytarabine, and cisplatin in combination
with rituximab as salvage treatment for patients with relapsed or
refractory aggressive non-Hodgkin’s lymphoma. Cancer Invest.
24:593–600. 2006.
|
|
32
|
Josting A, Sieniawski M, Glossmann JP, et
al: High-dose sequential chemotherapy followed by autologous stem
cell transplantation in relapsed or refractory aggressive
non-Hodgkin’s lymphoma: results of a multicentric phase II study.
Ann Oncol. 16:1359–1365. 2005.
|
|
33
|
Vellenga E, van Putten WL, van’t Veer MB,
et al: Rituximab improves the treatment results of DHAP-VIM-DHAP
and ASCT in relapsed/progressive aggressive CD20+ NHL: a
prospective randomized HOVON trial. Blood. 111:537–543. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Park SH, Kim S, Ko OB, et al: ESHAP
salvage therapy for refractory and relapsed non-Hodgkin’s lymphoma:
a single center experience. Korean J Intern Med. 21:159–164.
2006.
|
|
35
|
Martin A, Conde E, Arnan M, et al: R-ESHAP
as salvage therapy for patients with relapsed or refractory diffuse
lsrge B-cell lymphoma: the influence of prior exposure to rituximab
on outcome. Haematologica. 93:1829–1836. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sorà F, Piccirillo N, Chiusolo P, et al:
Mitoxantrone, carboplatin, cytosine arabinoside, and
methylprednisolone followed by autologous peripheral blood stem
cell transplantation. Cancer. 106:859–866. 2006.PubMed/NCBI
|
|
37
|
Atta J, Chow KU, Weidmann E, Mitrou PS,
Hoelzer D and Martin H: Dexa-BEAM as salvage therapy in patients
with primary refractory aggressive non-Hodgkin lymphoma. Leuk
Lymphoma. 48:349–356. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jermann M, Jost LM, Taverna CH, et al:
Rituximab-EPOCH, an effective salvage therapy for relapsed,
refractory or transformed B-cell lymphomas: results of a phase II
study. Ann Oncol. 15:511–516. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang M, Fayad L, Cabanillas F, et al:
Phase-2 trial of rituximab plus HyperCVAD alternating with
rituximab plus methotrexate – cytarabine for relapsed or refractory
aggressive mantle cell lymphoma. Cancer. 113:2734–2741. 2008.
|
|
40
|
Robak T, Lech-Maranda E, Janus A, Blonski
J, Wierzbowska A and Gora-Tybor J: Cladribine combined with
cyclophosphamide and mitoxantrone is an active salvage therapy in
advanced non-Hodgkin’s lymphoma. Leuk Lymphoma. 48:1092–1101.
2007.
|
|
41
|
Zwick C, Birkmann J, Peter N, et al:
Equitoxicity of bolus and infusional etoposide: results of a multi
center randomised trial of the German High-Grade Non-Hodgkin
Lymphoma Study Group (DSHNHL) in elderly patients with refractory
or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen
(cisplatinum, etoposide, mitoxantrone and prednisone). Ann Hematol.
87:717–726. 2008.
|
|
42
|
Sud R and Friedberg JW: Salvage therapy
for relapsed or refractory diffuse large B-cell lymphoma: impact of
prior rituximab. Haematologica. 93:1776–1780. 2008. View Article : Google Scholar : PubMed/NCBI
|
